Literature DB >> 23526821

In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.

Kateryna Soloviova1, Maksym Puliaiev, Mark Haas, Charles S Via.   

Abstract

A third signal is required for maturation of effector CD8 CTL in addition to TCR and CD28 engagement. Inflammatory cytokines can provide a third signal; however, in nonpathogen settings (i.e., antitumor responses), the identity of the third signal is not clear. A useful model for in vivo CD8 CTL in the absence of exogenous pathogens is the alloantigen-driven parent-into F1 model of acute graft-versus-host disease (GVHD) characterized by a strong TNF-dependent donor antihost CD8 CTL T cell response. To determine whether TNF acts directly on donor T cells in a signal 3 manner, F1 mice received TNFR 1 (p55) knockout (KO) and/or TNFR 2 (p75) KO donor T cells. Donor p75 KO but not p55KO donor T cells failed to induce acute GVHD phenotype and instead induced a lupus-like chronic GVHD both short and long term because of quantitative and qualitative donor T cell defects, that is, reduced perforin, IFN-γ, and TNF production. Transfer of mixed or matched purified CD4 and CD8 T cells from wild type or p75KO donors demonstrated that optimal CTL maturation required p75 signaling in both CD4 and CD8 T cells. Despite defective p75KO CD4 help for CD8 CTL, p75KO CD4 help for B cells and autoimmunity was intact. These results provide a mechanism by which impaired CD8 CTL could contribute to reduced antiviral and antitumor responses and autoimmunity reported in patients receiving TNF blockers. Our results support the idea that selective p55 blockade may be beneficial by reducing inflammation without compromising CD8 CTL.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23526821      PMCID: PMC3633743          DOI: 10.4049/jimmunol.1300091

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  Signal 3 availability limits the CD8 T cell response to a solid tumor.

Authors:  Julie M Curtsinger; Michael Y Gerner; Debra C Lins; Matthew F Mescher
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

Review 2.  Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE.

Authors:  I Puliaeva; R Puliaev; C S Via
Journal:  Autoimmun Rev       Date:  2008-08-24       Impact factor: 9.754

3.  T cell TRAIL promotes murine lupus by sustaining effector CD4 Th cell numbers and by inhibiting CD8 CTL activity.

Authors:  Violeta Rus; Vinh Nguyen; Roman Puliaev; Irina Puliaeva; Valentina Zernetkina; Irina Luzina; John C Papadimitriou; Charles S Via
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

4.  CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Authors:  Roman Puliaev; Irina Puliaeva; Lisbeth A Welniak; Abigail E Ryan; Mark Haas; William J Murphy; Charles S Via
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

5.  Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist.

Authors:  Hiroko Shibata; Yasuo Yoshioka; Akiko Ohkawa; Kyoko Minowa; Yohei Mukai; Yasuhiro Abe; Madoka Taniai; Tetsuya Nomura; Hiroyuki Kayamuro; Hiromi Nabeshi; Toshiki Sugita; Sunao Imai; Kazuya Nagano; Tomoaki Yoshikawa; Takuya Fujita; Shinsaku Nakagawa; Akira Yamamoto; Tsunetaka Ohta; Takao Hayakawa; Tadanori Mayumi; Peter Vandenabeele; Bharat B Aggarwal; Teruya Nakamura; Yuriko Yamagata; Shin-ichi Tsunoda; Haruhiko Kamada; Yasuo Tsutsumi
Journal:  J Biol Chem       Date:  2007-11-14       Impact factor: 5.157

Review 6.  Autoantibody production in anti-TNF-alpha-treated patients.

Authors:  Cristiano Alessandri; Rossana Scrivo; Francesca Romana Spinelli; Fulvia Ceccarelli; Leonardo Magrini; Roberta Priori; Guido Valesini
Journal:  Ann N Y Acad Sci       Date:  2007-09       Impact factor: 5.691

Review 7.  TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature.

Authors:  Bijay Nair; Girindra Raval; Paulette Mehta
Journal:  Am J Hematol       Date:  2007-11       Impact factor: 10.047

8.  Fas expression on antigen-specific T cells has costimulatory, helper, and down-regulatory functions in vivo for cytotoxic T cell responses but not for T cell-dependent B cell responses.

Authors:  Irina Puliaeva; Roman Puliaev; Andrei Shustov; Mark Haas; Charles S Via
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

Review 9.  Pathophysiology of acute graft-versus-host disease: recent advances.

Authors:  Yaping Sun; Isao Tawara; Tomomi Toubai; Pavan Reddy
Journal:  Transl Res       Date:  2007-07-03       Impact factor: 7.012

Review 10.  Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.

Authors:  Matthew B Carroll; Michael I Bond
Journal:  Semin Arthritis Rheum       Date:  2008-01-25       Impact factor: 5.532

View more
  10 in total

1.  In vivo IL-4 prevents allo-antigen driven CD8+ CTL development.

Authors:  Charles S Via; Kateryna Soloviova; Maksym Puliaiev; Roman Puliav; Irina Puliaeva; Suzanne C Morris; Fred D Finkelman
Journal:  Clin Immunol       Date:  2017-03-27       Impact factor: 3.969

2.  B cell depletion in murine lupus using cytotoxic T lymphocytes in vivo: Feasibility and benefit.

Authors:  Kateryna Soloviova; Irina Puliaeva; Maksym Puliaiev; Roman Puliaev; Charles S Via
Journal:  Cell Immunol       Date:  2020-05-05       Impact factor: 4.868

3.  Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.

Authors:  Martin Chopra; Andreas Brandl; Daniela Siegmund; Anja Mottok; Viktoria Schäfer; Marlene Biehl; Sabrina Kraus; Carina A Bäuerlein; Miriam Ritz; Katharina Mattenheimer; Stefanie Schwinn; Axel Seher; Thomas Grabinger; Hermann Einsele; Andreas Rosenwald; Thomas Brunner; Andreas Beilhack; Harald Wajant
Journal:  Blood       Date:  2015-05-26       Impact factor: 22.113

Review 4.  TNFR2 Costimulation Differentially Impacts Regulatory and Conventional CD4+ T-Cell Metabolism.

Authors:  Mark Mensink; Thi Ngoc Minh Tran; Esther A Zaal; Ellen Schrama; Celia R Berkers; Jannie Borst; Sander de Kivit
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

5.  Intrinsic Differences in Donor CD4 T Cell IL-2 Production Influence Severity of Parent-into-F1 Murine Lupus by Skewing the Immune Response Either toward Help for B Cells and a Sustained Autoantibody Response or toward Help for CD8 T Cells and a Downregulatory Th1 Response.

Authors:  Kateryna Soloviova; Maksym Puliaiev; Mark Haas; Clifton L Dalgard; Brian C Schaefer; Charles S Via
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

Review 6.  Insights into the biology and therapeutic implications of TNF and regulatory T cells.

Authors:  Benoit L Salomon
Journal:  Nat Rev Rheumatol       Date:  2021-07-05       Impact factor: 20.543

7.  Macrophage TNF-α licenses donor T cells in murine bone marrow failure and can be implicated in human aplastic anemia.

Authors:  Wanling Sun; Zhijie Wu; Zenghua Lin; Maile Hollinger; Jichun Chen; Xingmin Feng; Neal S Young
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

8.  Hybrid cytokine IL233 renders protection in murine acute graft vs host disease (aGVHD).

Authors:  Rajkumar Venkatadri; Vikram Sabapathy; Murat Dogan; Rohan Sharma; Saleh Mohammad; Charles S Via; Rahul Sharma
Journal:  Cell Immunol       Date:  2021-03-23       Impact factor: 4.178

9.  CXCL13, CCL4, and sTNFR as circulating inflammatory cytokine markers in primary and SLE-related autoimmune hemolytic anemia.

Authors:  Boting Wu; Weiguang Wang; Yanxia Zhan; Feng Li; Shanhua Zou; Lihua Sun; Yunfeng Cheng
Journal:  J Transl Med       Date:  2015-04-08       Impact factor: 5.531

Review 10.  Targeting Regulatory T Cells by Addressing Tumor Necrosis Factor and Its Receptors in Allogeneic Hematopoietic Cell Transplantation and Cancer.

Authors:  Harald Wajant; Andreas Beilhack
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.